Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | Cr.O4P |
| Molecular Weight | 147.9676 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cr+3].[O-][32P]([O-])([O-])=O
InChI
InChIKey=IKZBVTPSNGOVRJ-ZYUMTRPDSA-K
InChI=1S/Cr.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+3;/p-3/i;5+1
| Molecular Formula | O4P |
| Molecular Weight | 95.9715 |
| Charge | -3 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Cr |
| Molecular Weight | 51.9961 |
| Charge | 3 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine and biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | SODIUM PHOSPHATE P 32 Approved UseP32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases Launch Date1959 |
|||
| Primary | SODIUM PHOSPHATE P 32 Approved UseP32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases Launch Date1959 |
|||
| Primary | SODIUM PHOSPHATE P 32 Approved UseP32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases Launch Date1959 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:59:57 GMT 2025
by
admin
on
Mon Mar 31 17:59:57 GMT 2025
|
| Record UNII |
QHO02LZ4H2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000000205
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
||
|
NDF-RT |
N0000175872
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
||
|
NCI_THESAURUS |
C2124
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
24381-60-0
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
PRIMARY | |||
|
121070
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB13361MIG
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
PRIMARY | |||
|
m3501
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
PRIMARY | Merck Index | ||
|
71383
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
PRIMARY | |||
|
C61676
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
PRIMARY | |||
|
QHO02LZ4H2
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110568
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
PRIMARY | |||
|
100000086308
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
PRIMARY | |||
|
DTXSID20947246
Created by
admin on Mon Mar 31 17:59:57 GMT 2025 , Edited by admin on Mon Mar 31 17:59:57 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |